Scalper1 News
2015 was a year with two distinct parts for drug stocks: The first seven months continued the bull run of the last four years, while the sudden resurfacing of the drug-pricing debate led to a rocky five months after that. But overall, the group came out ahead — and these top-performing big caps show that a solid story can make up for political worries in the eyes of investors. Incyte (INCY) is up 49% — as of Wednesday’s close — after a year of Scalper1 News
Scalper1 News